UCB (OTCMKTS:UCBJY) Reaches New 12-Month Low – Here’s Why

UCB SA (OTCMKTS:UCBJY) hit a new 52-week low during mid-day trading on Wednesday. The stock traded as low as $116.29 and last traded at $116.38, with a volume of 6770 shares traded. The stock had previously closed at $117.61.

Analyst Ratings Changes

UCBJY has been the topic of a number of research analyst reports. Barclays lowered shares of UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Zacks Research downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 16th. Finally, Jefferies Financial Group upgraded shares of UCB from a “moderate sell” rating to a “hold” rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy”.

UCB Trading Down 0.5%

The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38. The firm has a 50 day moving average price of $126.53 and a 200-day moving average price of $138.49.

About UCB

UCB SA is a Belgium-based biopharmaceutical company that discovers, develops and commercializes medicines for severe diseases, with a primary focus on neurology and immunology. The company serves patients and healthcare professionals in markets around the world through its research, manufacturing and commercial operations.

UCB’s medicines include Bimzelx (bimekizumab), used to treat several inflammatory conditions; Cimzia (certolizumab pegol), an immunology therapy; and Fintepla (fenfluramine), a treatment for certain severe epileptic syndromes.